POSTER PRESENTATION AACR 2023
Optimization of screening conditions using patient-derived organoids for diagnostic purposes
Patient-derived organoids (PDOs), also known as HUB Organoids®, are becoming increasingly popular in preclinical research. These organoids are established directly from patient tissue, accurately mimicking the patient's disease and acting as a bridge between the lab and the clinic, allowing for "patient in the lab®" research. PDOs can predict patient response to standard-of-care compounds, but the assay conditions need refinement to evaluate SoC drugs with different mechanisms of action and molecule types. For metastatic colorectal cancer (mCRC), our team has optimized the media composition for drug screening and developed an imaging-based readout to accurately quantify organoid numbers and deliver robust data from this assay. Optimal media conditions are crucial for replicating the original patient disease in vitro and mirroring patient response in the clinic.
Download this poster to discover:
- Insights into the optimization of our screening protocol, which involved testing various factors, such as the type of solvent, compound concentration, and medium composition.
- Outline of our fine-tuned imaging assay for organoid screening
- The comparison between Cell Titer-Glo and alternative fluorescent dye for imaging-based readouts